Subtopic Deep Dive
Gene Expression Profiling in CUP Classification
Research Guide
What is Gene Expression Profiling in CUP Classification?
Gene expression profiling in CUP classification uses molecular assays to identify tissue-of-origin in cancers of unknown primary site through gene expression signatures.
Commercial assays like CancerTYPE ID and Pathwork apply 92-gene or microarray profiling to metastatic tumors (Ma et al., 2006; 198 citations). Studies validate accuracy against autopsy benchmarks and clinical outcomes (Pentheroudakis et al., 2007; 258 citations). Over 10 key papers since 2005 demonstrate 80-90% prediction rates in CUP cohorts (Tothill et al., 2005; 217 citations).
Why It Matters
Gene expression profiling enables site-specific therapies in CUP, improving survival over empiric chemotherapy, as shown in a randomized trial where profiling-directed treatment extended progression-free survival (Hayashi et al., 2019; 164 citations). It refines CUP taxonomy for precision oncology, identifying actionable mutations in 30-50% of cases (Ross et al., 2015; 238 citations). ESMO guidelines endorse molecular profiling for favorable-subset CUP to guide targeted agents (Krämer et al., 2022; 170 citations; Fizazi et al., 2011; 166 citations).
Key Research Challenges
Prediction Accuracy Variability
Assay accuracy drops in poorly differentiated or pretreated CUP tumors, with concordance rates of 70-85% versus autopsy (Pentheroudakis et al., 2007). Multi-platform comparisons reveal 20-30% discordance between microarray and RT-PCR methods (Tothill et al., 2005; Ma et al., 2006).
Clinical Outcome Correlation
Profiling-directed therapy shows PFS benefit but inconsistent OS gains in randomized trials (Hayashi et al., 2019). Lack of large-scale validation limits guideline adoption beyond select CUP subsets (Fizazi et al., 2011).
Integration with Genomics
Combining gene expression with NGS identifies drivers but complicates primary predictions in heterogeneous CUP (Ross et al., 2015). MicroRNA assays improve specificity yet face reproducibility issues across cohorts (Meiri et al., 2012; Ferracin et al., 2011).
Essential Papers
Switching benchmarks in cancer of unknown primary: From autopsy to microarray
George Pentheroudakis, Vassilios Golfinopoulos, Nicholas Pavlidis · 2007 · European Journal of Cancer · 258 citations
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site
Jeffrey S. Ross, Kai Wang, Laurie M. Gay et al. · 2015 · JAMA Oncology · 238 citations
Importance For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome. Objective To discover opportunities for targeted ...
An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin
Richard W. Tothill, Adam Kowalczyk, Danny Rischin et al. · 2005 · Cancer Research · 217 citations
Abstract Gene expression profiling offers a promising new technique for the diagnosis and prognosis of cancer. We have applied this technology to build a clinically robust site of origin classifier...
Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay
Xiaojun Ma, R. D. Patel, Xianqun Wang et al. · 2006 · Archives of Pathology & Laboratory Medicine · 198 citations
Abstract Context.—Correct diagnosis of the tissue origin of a metastatic cancer is the first step in disease management, but it is frequently difficult using standard pathologic methods. Microarray...
The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review
Ondřej Kubeček, Ján Laco, Jiří Špaček et al. · 2017 · Clinical & Experimental Metastasis · 172 citations
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Krämer, Tilmann Bochtler, Chantal Pauli et al. · 2022 · Annals of Oncology · 170 citations
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Karim Fizazi, F. Anthony Greco, Nicholas Pavlidis et al. · 2011 · Annals of Oncology · 166 citations
Reading Guide
Foundational Papers
Start with Pentheroudakis et al. (2007; 258 citations) for autopsy-microarray benchmarks, then Tothill et al. (2005; 217 citations) for classifier design, and Ma et al. (2006; 198 citations) for 92-gene RT-PCR validation.
Recent Advances
Hayashi et al. (2019; 164 citations) for randomized trial outcomes; Ross et al. (2015; 238 citations) for genomic profiling; Krämer et al. (2022; 170 citations) for updated ESMO guidelines.
Core Methods
Microarray classifiers (Tothill et al., 2005), 92-gene RT-qPCR (Ma et al., 2006), microRNA panels (Meiri et al., 2012), with prediction algorithms trained on 1,000+ tumor samples.
How PapersFlow Helps You Research Gene Expression Profiling in CUP Classification
Discover & Search
Research Agent uses searchPapers('gene expression profiling CUP classification') to retrieve 250+ OpenAlex papers, then citationGraph on Pentheroudakis et al. (2007; 258 citations) maps foundational works like Tothill et al. (2005), while findSimilarPapers expands to Hayashi et al. (2019) trial.
Analyze & Verify
Analysis Agent applies readPaperContent to Hayashi et al. (2019) for trial endpoints, verifyResponse (CoVe) cross-checks PFS claims against Fizazi et al. (2011), and runPythonAnalysis computes meta-analysis of accuracy rates from Ma et al. (2006) and Tothill et al. (2005) with GRADE B evidence grading for clinical utility.
Synthesize & Write
Synthesis Agent detects gaps in post-profiling OS data via contradiction flagging across Ross et al. (2015) and Krämer et al. (2022); Writing Agent uses latexEditText for assay comparison tables, latexSyncCitations for 10-paper bibliography, latexCompile for review draft, and exportMermaid for accuracy concordance flowcharts.
Use Cases
"Meta-analyze prediction accuracy of 92-gene assay vs microRNA in CUP cohorts"
Research Agent → searchPapers + findSimilarPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on Ma et al. 2006, Meiri et al. 2012) → GRADE-graded CSV export of pooled 82% accuracy.
"Draft LaTeX review on CUP profiling trials with ESMO guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Fizazi 2011, Krämer 2022) → latexCompile → PDF with integrated trial flowchart.
"Find GitHub code for CUP gene expression classifiers"
Research Agent → paperExtractUrls (Tothill 2005) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox verification of classifier scripts matching 92-gene assay.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers('CUP gene expression') → citationGraph → readPaperContent on top-20 → GRADE synthesis report on 85% average accuracy. DeepScan applies 7-step CoVe to Hayashi et al. (2019) trial, verifying endpoints against Pentheroudakis et al. (2007). Theorizer generates hypotheses on microRNA-gene expression hybrids from Meiri et al. (2012) and Ferracin et al. (2011).
Frequently Asked Questions
What defines gene expression profiling in CUP classification?
It uses RT-PCR or microarray assays like 92-gene panel to predict tissue-of-origin from metastatic CUP biopsies (Ma et al., 2006).
What are key methods in CUP profiling?
92-gene RT-qPCR (Ma et al., 2006), microarray classifiers (Tothill et al., 2005), and microRNA signatures (Meiri et al., 2012; Ferracin et al., 2011).
What are seminal papers?
Pentheroudakis et al. (2007; 258 citations) benchmarks microarray vs autopsy; Tothill et al. (2005; 217 citations) builds clinical classifier; Hayashi et al. (2019; 164 citations) validates therapy guidance.
What open problems remain?
OS benefits from profiling-directed therapy unproven in phase III; integration with NGS for heterogeneous CUP unresolved (Ross et al., 2015; Krämer et al., 2022).
Research Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gene Expression Profiling in CUP Classification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Diagnosis and Treatment Research Guide